Parkinson Disease

Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and nonmotor symptoms in Parkinson disease.

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

Phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early-stage Parkinson's disease.

Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins.

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.

In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

Full results from the phase 3 TEMPO-2 trial, published in Lancet Neurology, showed that flexible-dose tavapadon significantly improved motor symptoms and daily function in people with early Parkinson disease.

A recently published phase 2 trial showed that CBD/THC cannabis oil failed to ease chronic pain or nonmotor symptoms versus placebo among patients with Parkinson disease.

Investigators independently tracked the 6 patients treated in a Parkinson disease gene therapy trial that was abandoned mid-study after its sponsor became insolvent, finding a reassuring safety profile and mixed signals of motor benefit through up to 3 years.

Topline findings from the Phase 2 SUNRISE-PD study showed statistically significant improvements in clinical measures, inflammatory biomarkers, and exploratory neurodegeneration markers among patients with early Parkinson disease treated with bezisterim.

The FDA has granted Regenerative Medicine Advanced Therapy designation to sasineprocel, an autologous cell therapy for Parkinson disease, based on early data from the ongoing ASPIRO trial.